Literature DB >> 2154332

The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T.

J W Ludlow1, J Shon, J M Pipas, D M Livingston, J A DeCaprio.   

Abstract

Synchronized monkey cells pulse-labeled with [35S]-methionine and chased for various lengths of time were extracted, and immunoprecipitations were performed using monoclonal antibodies directed against the retinoblastoma protein (RB) and SV40 T antigen (T). By following a discrete population of these two proteins through the cell cycle, the following information was obtained. RB, which is wholly unphosphorylated in G1, became phosphorylated at the beginning of S and remained phosphorylated through S and G2. RB was, then, completely dephosphorylated between the end of G2 and the beginning of G1. Second, while all of the detectable unphosphorylated RB can be found complexed with T, these complexes present during G1 dissociated in S and reformed again in M or early G1. Finally, T molecules appeared to oligomerize prior to binding RB. Thus, complex formation between T and RB may be regulated in part by the cell cycle-dependent phosphorylation and dephosphorylation of RB and by the quaternary structure of T.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154332     DOI: 10.1016/0092-8674(90)90590-b

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  112 in total

1.  Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts.

Authors:  Tina M Beachy; Sara L Cole; Jane F Cavender; Mary J Tevethia
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Development and characterization of a mouse floxed Bmp2 osteoblast cell line that retains osteoblast genotype and phenotype.

Authors:  Li-an Wu; Junsheng Feng; Lynn Wang; Yan-dong Mu; Andrew Baker; Kevin J Donly; Stephen E Harris; Mary MacDougall; Shuo Chen
Journal:  Cell Tissue Res       Date:  2011-01-27       Impact factor: 5.249

3.  Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.

Authors:  S E Abraham; M C Carter; E Moran
Journal:  Mol Biol Cell       Date:  1992-06       Impact factor: 4.138

4.  Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene.

Authors:  P A Hamel; R M Gill; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

5.  Identification of a 60-kilodalton Rb-binding protein, RBP60, that allows the Rb-E2F complex to bind DNA.

Authors:  S K Ray; M Arroyo; S Bagchi; P Raychaudhuri
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

Review 6.  Nuclear protein phosphorylation and growth control.

Authors:  D W Meek; A J Street
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

Review 7.  Simian virus 40 large T antigen: the puzzle, the pieces, and the emerging picture.

Authors:  E Fanning
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.

Authors:  J A DeCaprio; Y Furukawa; F Ajchenbaum; J D Griffin; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest.

Authors:  G S Dbaibo; M Y Pushkareva; S Jayadev; J K Schwarz; J M Horowitz; L M Obeid; Y A Hannun
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.